It lost $98.4 million, which comes to -$0.11 EPS, and that is down from -$156.6 million and -$0.20 EPS a year ago. Revenues were down about 1% to $6.53 billion. Thomson Reuters had estimates at -$0.13 EPS and $6.55 billion in revenues.
The company now expects a wider loss for the year, although this appears to be based upon refinancing expenses. A larger interest expense than originally seen is the culprit. It has started refinancing a portion of its September 2010 maturities.
The issue to consider here is that its same-store sales actually grew by +0.6% as prescriptions rose by +2.2% for the quarter. The company also noted that net cash provided by operations was $357.6 million and its liquidity grew to $901.8 million at the end of the quarter.
Trading volume is still a bit light this morning but shares are indicated up 3% at $1.30 in pre-market trading. The 52-week range is $0.20 to $1.97.
Jon C. Ogg
June 24, 2009